CABA News and Press, Cabaletta Bio Inc. From 11/09/23

Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...

Cabaletta Bio Inc. (CABA) is expected to report $-0.39 for Q3 2023

Collaboration with intent to validate Cellares’ Cell Shuttle platform for manufacturing of CABA-201, Cabaletta Bio’s fully human CD19-CAR T product candidate, which is being evaluated in parallel phase 1/2 trials across multiple autoimmune diseases Cellares , the fir...

PHILADELPHIA, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that the Company will participate in thr...

2023-10-25 16:30:06 ET More on Cabaletta Bio Cabaletta Bio: How Long Can Unique Cell Therapy Developer's Sensational Bull Run Continue? Cabaletta Bio director purchases, sells shares in company Seeking Alpha’s Quant Rating on Cabaletta Bio Historical e...

Cabaletta Bio, Inc. (NASDAQ: CABA) is the focus of IBN's latest stock spotlight. The company's shares have moved 8.68% on the day to $13.28. Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B ...

Cabaletta Bio, Inc. (NASDAQ: CABA) is the focus of IBN's latest stock spotlight. The company's shares have moved -8.64% on the day to $12.26. Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B...

– Third IND application clearance for CABA-201 within the past 6 months across a broad range of autoimmune diseases – – Phase 1/2 clinical trial evaluating CABA-201 in systemic sclerosis features parallel cohort design and the same starting dose as the CABA-201 INDs...

2023-09-21 14:45:57 ET More on Cabaletta Bio Seeking Alpha’s Quant Rating on Cabaletta Bio Historical earnings data for Cabaletta Bio Financial information for Cabaletta Bio Cabaletta Bio: How Long Can Unique Cell Therapy Developer's Sensational Bull R...

2023-09-19 04:56:57 ET Summary Cabaletta Bio stock has experienced a significant bull run, rising over 2,100% in the past year. The company's focus on autoimmune conditions with a validated cell therapy approach, rather than oncology, has been a key factor in its success. Caba...